Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Key PointsNovo has experienced several setbacks, especially in its core therapeutic area.
Key PointsNovo has experienced several setbacks, especially in its core therapeutic area.